Rocbrutinib
Rocbrutinib is an investigational new drug that is being evaluated by Newave Pharmaceuticals for the treatment of chronic lymphocytic leukaemia (CLL), diffuse large B cell lymphoma (DLBCL), and mantle cell lymphoma (MCL).
≈ 1 min read
Names in other languages
No names in other languages are held for this entry yet.
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
Rocbrutinib is an investigational new drug that is being evaluated by Newave Pharmaceuticals for the treatment of chronic lymphocytic leukaemia (CLL), diffuse large B cell lymphoma (DLBCL), and mantle cell lymphoma (MCL). It is a Bruton's tyrosine kinase (BTK) inhibitor.
Text derived from https://en.wikipedia.org/w/index.php?oldid=1368214624 under CC BY-SA 4.0; modifications have been made.